Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1991 Dec;88(6):1833–1840. doi: 10.1172/JCI115504

The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells.

K K Hamilton 1, P J Sims 1
PMCID: PMC295750  PMID: 1752944

Abstract

Terminal complement protein complexes C5b-9 have been found in human atherosclerotic lesions. Insertion of C5b-9 in the endothelial cell membrane alters permeability, induces membrane vesiculation, and activates secretion. We hypothesized that complement might also alter interactions of the endothelial surface with lipoproteins, particularly high density lipoprotein (HDL), which is reported to inhibit C5b-9-induced hemolysis. We now demonstrate that exposure to C5b-9 increases (by 2- to 50-fold) specific binding of HDL and its apolipoproteins (apo) A-I and A-II to endothelial cells. Binding to cells exposed to antibody, C5b67, and C5b-8 was virtually unchanged. Enhanced binding was also dependent on the number of C5b-9 complexes deposited on the cells. Other agonists that activate endothelial secretion did not augment binding. Calcium was required for full exposure of new binding sites by C5b-9. The C5b-9-induced increase in binding was independent of the increase observed after cholesterol loading. In addition, apo A-I and A-II appear to compete for the same binding sites on untreated and C5b-9-treated cells. In contrast to the data reported for red cells, we were unable to detect significant inhibition of C5b-9-mediated endothelial membrane permeabilization by HDL (up to 1 mg/ml) or by apo A-I (up to 100 micrograms/ml). These data demonstrate that the C5b-9 proteins enhance endothelial binding of HDL and its apoproteins, suggesting that intravascular complement activation may alter cholesterol homeostasis in the vessel wall.

Full text

PDF
1833

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anantharamaiah G. M., Hughes T. A., Iqbal M., Gawish A., Neame P. J., Medley M. F., Segrest J. P. Effect of oxidation on the properties of apolipoproteins A-I and A-II. J Lipid Res. 1988 Mar;29(3):309–318. [PubMed] [Google Scholar]
  2. Andreoli S. P., Baehner R. L., Bergstein J. M. In vitro detection of endothelial cell damage using 2-deoxy-D-3H-glucose: comparison with chromium 51, 3H-leucine, 3H-adenine, and lactate dehydrogenase. J Lab Clin Med. 1985 Sep;106(3):253–261. [PubMed] [Google Scholar]
  3. Barbaras R., Puchois P., Fruchart J. C., Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun. 1987 Jan 15;142(1):63–69. doi: 10.1016/0006-291x(87)90451-7. [DOI] [PubMed] [Google Scholar]
  4. Brinton E. A., Kenagy R. D., Oram J. F., Bierman E. L. Regulation of high density lipoprotein binding activity of aortic endothelial cells by treatment with acetylated low density lipoprotein. Arteriosclerosis. 1985 Jul-Aug;5(4):329–335. doi: 10.1161/01.atv.5.4.329. [DOI] [PubMed] [Google Scholar]
  5. Brown M. S., Ho Y. K., Goldstein J. L. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem. 1980 Oct 10;255(19):9344–9352. [PubMed] [Google Scholar]
  6. Edelstein C., Lim C. T., Scanu A. M. On the subunit structure of the protein of human serum high density lipoprotein. I. A study of its major polypeptide component (Sephadex, fraction 3). J Biol Chem. 1972 Sep 25;247(18):5842–5849. [PubMed] [Google Scholar]
  7. Epand R. M., Segrest J. P., Anantharamaiah G. M. Thermodynamics of the binding of human apolipoprotein A-I to dimyristoylphosphatidylglycerol. J Biol Chem. 1990 Dec 5;265(34):20829–20832. [PubMed] [Google Scholar]
  8. Esser A. F., Kolb W. P., Podack E. R., Müller-Eberhard H. J. Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranolysis. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1410–1414. doi: 10.1073/pnas.76.3.1410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Esser A. F. The membrane attack pathway of complement. Year Immunol. 1989;6:229–244. [PubMed] [Google Scholar]
  10. Gordon D. J., Rifkind B. M. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989 Nov 9;321(19):1311–1316. doi: 10.1056/NEJM198911093211907. [DOI] [PubMed] [Google Scholar]
  11. Graham D. L., Oram J. F. Identification and characterization of a high density lipoprotein-binding protein in cell membranes by ligand blotting. J Biol Chem. 1987 Jun 5;262(16):7439–7442. [PubMed] [Google Scholar]
  12. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hamilton K. K., Hattori R., Esmon C. T., Sims P. J. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990 Mar 5;265(7):3809–3814. [PubMed] [Google Scholar]
  14. Hara H., Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 1991 Feb 15;266(5):3080–3086. [PubMed] [Google Scholar]
  15. Hattori R., Hamilton K. K., Fugate R. D., McEver R. P., Sims P. J. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem. 1989 May 15;264(14):7768–7771. [PubMed] [Google Scholar]
  16. Hattori R., Hamilton K. K., McEver R. P., Sims P. J. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989 May 25;264(15):9053–9060. [PubMed] [Google Scholar]
  17. Havekes L., Schouten D., van Hinsbergh V., de Wit E. Characterisation of the binding of apolipoprotein E-free high density lipoprotein to cultured human endothelial cells. Biochem Biophys Res Commun. 1984 Jul 31;122(2):785–790. doi: 10.1016/s0006-291x(84)80102-3. [DOI] [PubMed] [Google Scholar]
  18. Jenne D. E., Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7123–7127. doi: 10.1073/pnas.86.18.7123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kunitake S. T., La Sala K. J., Kane J. P. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res. 1985 May;26(5):549–555. [PubMed] [Google Scholar]
  20. Maciejko J. J., Holmes D. R., Kottke B. A., Zinsmeister A. R., Dinh D. M., Mao S. J. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983 Aug 18;309(7):385–389. doi: 10.1056/NEJM198308183090701. [DOI] [PubMed] [Google Scholar]
  21. Matz C. E., Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem. 1982 Apr 25;257(8):4535–4540. [PubMed] [Google Scholar]
  22. McVicar J. P., Kunitake S. T., Hamilton R. L., Kane J. P. Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1356–1360. doi: 10.1073/pnas.81.5.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mendel C. M., Kunitake S. T., Kane J. P., Kempner E. S. Radiation inactivation of binding sites for high density lipoproteins in human fibroblast membranes. J Biol Chem. 1988 Jan 25;263(3):1314–1319. [PubMed] [Google Scholar]
  24. Morishita H., Yui Y., Hattori R., Aoyama T., Kawai C. Increased hydrolysis of cholesteryl ester with prostacyclin is potentiated by high density lipoprotein through the prostacyclin stabilization. J Clin Invest. 1990 Dec;86(6):1885–1891. doi: 10.1172/JCI114920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Oram J. F., Brinton E. A., Bierman E. L. Regulation of high density lipoprotein receptor activity in cultured human skin fibroblasts and human arterial smooth muscle cells. J Clin Invest. 1983 Nov;72(5):1611–1621. doi: 10.1172/JCI111120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Osborne J. C., Jr Delipidation of plasma lipoproteins. Methods Enzymol. 1986;128:213–222. doi: 10.1016/0076-6879(86)28069-6. [DOI] [PubMed] [Google Scholar]
  27. Packman C. H., Rosenfeld S. I., Leddy J. P. High-density lipoprotein and its apolipoproteins inhibit cytolytic activity of complement. Studies on the nature of inhibitory moiety. Biochim Biophys Acta. 1985 Jan 10;812(1):107–115. doi: 10.1016/0005-2736(85)90527-9. [DOI] [PubMed] [Google Scholar]
  28. Rosenfeld S. I., Packman C. H., Leddy J. P. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins. J Clin Invest. 1983 Apr;71(4):795–808. doi: 10.1172/JCI110833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Savion N., Gamliel A. Binding of apolipoprotein A-I and apolipoprotein A-IV to cultured bovine aortic endothelial cells. Arteriosclerosis. 1988 Mar-Apr;8(2):178–186. doi: 10.1161/01.atv.8.2.178. [DOI] [PubMed] [Google Scholar]
  30. Segrest J. P., Jackson R. L., Morrisett J. D., Gotto A. M., Jr A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett. 1974 Jan 15;38(3):247–258. doi: 10.1016/0014-5793(74)80064-5. [DOI] [PubMed] [Google Scholar]
  31. Seifert P. S., Hansson G. K. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989 Nov-Dec;9(6):802–811. doi: 10.1161/01.atv.9.6.802. [DOI] [PubMed] [Google Scholar]
  32. Seifert P. S., Hugo F., Hansson G. K., Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest. 1989 Jun;60(6):747–754. [PubMed] [Google Scholar]
  33. Slotte J. P., Oram J. F., Bierman E. L. Binding of high density lipoproteins to cell receptors promotes translocation of cholesterol from intracellular membranes to the cell surface. J Biol Chem. 1987 Sep 25;262(27):12904–12907. [PubMed] [Google Scholar]
  34. Suttorp N., Seeger W., Zinsky S., Bhakdi S. Complement complex C5b-8 induces PGI2 formation in cultured endothelial cells. Am J Physiol. 1987 Jul;253(1 Pt 1):C13–C21. doi: 10.1152/ajpcell.1987.253.1.C13. [DOI] [PubMed] [Google Scholar]
  35. Swaney J. B. Reconstitution of apolipoprotein A-I from human high density lipoprotein with bovine brain sphingomyelin. J Biol Chem. 1983 Jan 25;258(2):1254–1259. [PubMed] [Google Scholar]
  36. Tall A. R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 1990 Aug;86(2):379–384. doi: 10.1172/JCI114722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tauber J. P., Goldminz D., Gospodarowicz D. Up-regulation in vascular endothelial cells of binding sites of high density lipoprotein induced by 25-hydroxycholesterol. Eur J Biochem. 1981 Oct;119(2):327–339. doi: 10.1111/j.1432-1033.1981.tb05612.x. [DOI] [PubMed] [Google Scholar]
  38. Tauber J. P., Goldminz D., Vlodavsky I., Gospodarowicz D. The interaction of the high-density lipoprotein with cultured cells of bovine vascular endothelium. Eur J Biochem. 1981 Oct;119(2):317–325. doi: 10.1111/j.1432-1033.1981.tb05611.x. [DOI] [PubMed] [Google Scholar]
  39. Van der Meer B. W., Fugate R. D., Sims P. J. Complement proteins C5b-9 induce transbilayer migration of membrane phospholipids. Biophys J. 1989 Nov;56(5):935–946. doi: 10.1016/S0006-3495(89)82739-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Vlaicu R., Niculescu F., Rus H. G., Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis. 1985 Nov;57(2-3):163–177. doi: 10.1016/0021-9150(85)90030-9. [DOI] [PubMed] [Google Scholar]
  41. Wiedmer T., Sims P. J. Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J Biol Chem. 1985 Jul 5;260(13):8014–8019. [PubMed] [Google Scholar]
  42. Yui Y., Aoyama T., Morishita H., Takahashi M., Takatsu Y., Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest. 1988 Sep;82(3):803–807. doi: 10.1172/JCI113682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. de Silva H. V., Harmony J. A., Stuart W. D., Gil C. M., Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry. 1990 Jun 5;29(22):5380–5389. doi: 10.1021/bi00474a025. [DOI] [PubMed] [Google Scholar]
  44. de Silva H. V., Stuart W. D., Duvic C. R., Wetterau J. R., Ray M. J., Ferguson D. G., Albers H. W., Smith W. R., Harmony J. A. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem. 1990 Aug 5;265(22):13240–13247. [PubMed] [Google Scholar]
  45. van Tornout P., Caster H., Lievens M. J., Rosseneu M., Assmann G. In vitro interaction of human HDL with human apolipoprotein A-II. Synthesis of apolipoprotein A-II-rich HDL. Biochim Biophys Acta. 1981 Mar 23;663(3):630–636. doi: 10.1016/0005-2760(81)90073-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES